Floatz logo

Capivasertib

Recurrent Uterine Corpus Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Recurrent Uterine Corpus Carcinoma cohort.

Asset / SponsorPhaseRating
Ribociclib
Mayo Clinic
Phase 2B
Letrozole
Mayo Clinic
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Mirvetuximab Soravtansine
Ohio State University Comprehensive Cancer Center
Phase 1CCC
Pembrolizumab
Mayo Clinic
Phase 1/2CCC

View all 22 →

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Advanced Non-small-cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →